| Zeit | Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 15:23 | Kiora Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary | 1 | Reuters | ||
| 13:03 | Kiora Pharmaceuticals, Inc.: Kiora Pharmaceuticals Reports First Quarter Results; Update on Pipeline of Drugs Targeting Retinal Disease | 182 | Newsfile | Phase 2 trial for KIO-301 for the treatment of retinitis pigmentosa, in partnership with Théa Open Innovation, expected to be initiated in Q4 2024Phase 2 clinical trial for KIO-104 for retinal inflammation... ► Artikel lesen | |
| 13:02 | KIORA PHARMACEUTICALS INC - 8-K, Current Report | 2 | SEC Filings | ||
| 13:01 | KIORA PHARMACEUTICALS INC - 10-Q, Quarterly Report | 3 | SEC Filings | ||
| 12:59 | KIORA PHARMACEUTICALS INC - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| Mi | Kiora Pharmaceuticals, Inc.: Kiora Pharmaceuticals to Present at The Citizens JMP Life Sciences Conference | 133 | Newsfile | Encinitas, California--(Newsfile Corp. - May 8, 2024) - Kiora Pharmaceuticals (NASDAQ: KPRX) invites investors to view the Company's online presentation at The Citizens JMP Life Sciences Conference... ► Artikel lesen | |
| Mo | Kiora Pharmaceuticals, Inc.: Kiora Pharmaceuticals Reports Additional Clinical Data for KIO-301 Showing a Statistically Significant Increase in Brain Activity in the Visual Cortex in Patients with Retinitis Pigmentosa | 155 | Newsfile | Previously released ABACUS-1 clinical trial results reported KIO-301, a small molecule photoswitch, is safe, tolerable, and improved vision in patients with late-stage retinitis pigmentosa. Additional... ► Artikel lesen | |
| 11.04. | Kiora Pharmaceuticals, Inc.: Kiora Pharmaceuticals Receives Grant from Choroideremia Research Foundation to Fund Novel Clinical Trial Endpoints for Inherited Retinal Diseases; Approval Granted to Initiate Clinical Validation Study | 230 | Newsfile | Encinitas, California--(Newsfile Corp. - April 11, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) has received grant funding from the Choroideremia Research Foundation (CRF) in support of validating... ► Artikel lesen | |
| 05.04. | Kiora Pharmaceuticals, Inc.: Kiora Pharmaceuticals to Present at Upcoming Investor Conferences | 355 | Newsfile | Encinitas, California--(Newsfile Corp. - April 5, 2024) - Kiora Pharmaceuticals (NASDAQ: KPRX) invites investors to view the Company's online presentations from two upcoming investor conferences.Kiora... ► Artikel lesen | |
| 28.03. | Kiora Pharmaceuticals, Inc.: Kiora Pharmaceuticals to Present Additional Data from Its ABACUS-1 Trial in Retinitis Pigmentosa at the ARVO 2024 Annual Meeting | 259 | Newsfile | Encinitas, California--(Newsfile Corp. - March 28, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") announced that additional data from the ABACUS-1 trial has been accepted... ► Artikel lesen | |
| 25.03. | Kiora Pharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary | 2 | Reuters | ||
| 25.03. | Kiora Pharmaceuticals reports FY results | 2 | Seeking Alpha | ||
| 25.03. | KIORA PHARMACEUTICALS INC - 8-K, Current Report | 2 | SEC Filings | ||
| 25.03. | Kiora Pharmaceuticals, Inc.: Kiora Pharmaceuticals Reports 2023 Results; Continues to Advance Pipeline of Treatments for Rare Retinal Diseases | 358 | Newsfile | Encinitas, California--(Newsfile Corp. - March 25, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced its 2023 financial results and provided an update on... ► Artikel lesen | |
| 25.03. | KIORA PHARMACEUTICALS INC - 10-K, Annual Report | 2 | SEC Filings | ||
| 08.03. | Kiora Pharmaceuticals, Inc.: Kiora Announces Publication of Phase 1 Study Demonstrating Safety, Tolerability and Anti-Inflammatory Activity of KIO-101 in the Treatment of Inflammation of the Eye | 447 | Newsfile | Encinitas, California--(Newsfile Corp. - March 8, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") announced the publication of results from a Phase 1 double-masked study... ► Artikel lesen | |
| 12.02. | KIORA PHARMACEUTICALS INC - 8-K, Current Report | 4 | SEC Filings | ||
| 01.02. | Why Is Kiora Pharmaceuticals (KPRX) Stock Up 39% Today? | 22 | InvestorPlace | ||
| 01.02. | Kiora Pharmaceuticals, Inc.: Kiora Pharmaceuticals Announces Private Placement of up to Approximately $45 Million | 674 | Newsfile | Encinitas, California--(Newsfile Corp. - January 31, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company"), a clinical-stage biopharmaceutical company focused on developing... ► Artikel lesen | |
| 31.01. | Kiora Pharmaceuticals, Inc.: Kiora Pharmaceuticals and Théa Open Innovation Enter Strategic Agreement to Develop and Commercialize KIO-301 for the Treatment of Inherited Retinal Diseases; Total Deal Value of up to $301 Million includes $16 Million Upfront | 565 | Newsfile | Encinitas, California and Clermont-Ferrand, France--(Newsfile Corp. - January 31, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), a clinical-stage biotech company developing treatments for orphan... ► Artikel lesen |
Seite:
1 2 Weiter >>
| Suchbegriffe der letzen 24 h | Anzahl |
|---|---|
| EVOTEC | 2.823 |
| PLUG POWER | 2.587 |
| MERCEDES-BENZ | 2.412 |
| BAYER | 2.210 |
| NEL | 2.013 |
| TUI | 1.880 |
| SIEMENS ENERGY | 1.788 |
| ALLIANZ | 1.614 |
| PALANTIR TECHNOLOGIES | 1.360 |
| BYD | 1.283 |
| NVIDIA | 1.271 |
| RWE | 1.144 |
| DEUTSCHE BANK | 1.142 |
| NOVAVAX | 1.098 |
| DEUTSCHE LUFTHANSA | 998 |
| RHEINMETALL | 914 |
| VOLKSWAGEN | 914 |
| BASF | 897 |
| TESLA | 883 |
| RENK GROUP | 866 |
| INFINEON | 850 |
| NORDEX | 836 |
| SUPER MICRO COMPUTER | 797 |
| AIXTRON SE | 795 |
| COMMERZBANK | 786 |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
